plozalizumab plozalizumab plozalizumab (inn; hu1d9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency. plozalizumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetccr2clinical dataother nameshu1d9atc codenoneidentifierscas number1610761-46-0chemspidernoneunii4xg66bmn0dkeggd10972chemical and physical dataformulac6490h10052n1736o2018s42molar mass146032.46 g·mol−1 this drug was developed by takeda pharmaceuticals international co.